Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06347185
Other study ID # EORTC-2236-HNCG-QLG
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date December 2028

Study information

Verified date April 2024
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact EORTC HQ
Phone +3227741611
Email eortc@eortc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC) proposed to first line palliative systemic treatment. The study randomizes patients in a 1:1 fashion to standard oncologic care, in which the palliative care is requested as needed (reactive approach) or to early palliative care integrated with the standard oncologic care (proactive approach). Standard of Care: the oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient. Integrated approach: Besides the Oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H&N) and patient priority questionnaire's results. Stratification Factors - Institution - Performance Status (PS) (0 vs 1-2) - Presence of any caregiver at home - Type of treatment (Immunotherapy alone vs any other combination) Study duration: the total study duration is estimated at 36 months, with a total accrual time estimated to be 24 months from first patient in (FPI) and with an additional follow-up period of 12 months. End of study occurs when all patients have completed their end of study visit and the study is mature for all analyses defined in the protocol and the database has been cleaned and frozen for these analyses.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 160
Est. completion date December 2028
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over 18 years of age - Histological diagnosis of HNC of epithelial origin. Any sub-site of head and neck is eligible except endocrine tumours such as thyroid and parathyroid cancer - First diagnosis of recurrent disease and/or distant metastasis; with recurrent disease not amenable to salvage surgery or re-irradiation - Patient candidate to any first line systemic treatment - Life expectancy more than 3 months - PS Eastern Cooperative Oncology Group (ECOG) =2 - Adequate cognitive and reading abilities. - Availability of baseline scores for Emotional Functioning and Pain - Patient agrees to complete questionnaires at week 6, 15, 24 and 52 after systemic treatment start - Before patient 's enrolment, written informed consent must be given according to International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and national/local regulations. Exclusion Criteria: - Patients requiring a palliative care consultation right from the beginning of treatment - Cutaneous primary cancer - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Early palliative care, integrated with the standard oncologic care (proactive approach)
Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and patient priority questionnaire's results.
Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in emotional functioning and pain scores according to Item List (IL) 250 questionnaire at 15 weeks. To assess the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline to 15 weeks between arms in patient reported emotional functioning and pain.
Minimum = -100; Maximum = +100; higher means better outcome
at 15 weeks
Secondary Change from baseline in emotional functioning and pain scores according to Item List 250 (IL250) questionnaire at 6 weeks, 24 weeks and 52 weeks. Evaluate the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline at alternative timepoints between arms in patient reported emotional functioning and pain.
Minimum = -100; Maximum = +100; higher means better outcome
at 6 weeks, 24 weeks and 52 weeks
Secondary Change from baseline in the selected Health Related Quality of Life (HRQoL) scales from the Item List 250 (IL250) questionnaire at 6 weeks, 15 weeks, 24 weeks and 52 weeks Evaluate the change from baseline in supportive patient-reported symptom and functional outcomes at 6 weeks, 15 weeks, 24 weeks and 52 weeks.
Minimum = -100; Maximum = +100; higher means better outcome
at 6 weeks, 15 weeks, 24 weeks and 52 weeks
Secondary Number of unplanned visits to emergency room or specialist visits Evaluate the frequency of the unplanned access to emergency room or specialist visits up to 52 weeks
Secondary Hospitalization due to treatment toxicities or tumour signs/symptoms, as evaluated by number of admissions and duration Frequency of hospitalization due to adverse effects of treatment or due to tumour symptoms/signs up to 52 weeks
Secondary Identification of the rate of patients starting a new systemic treatment in the last three months of life Frequency of oncological treatments in last three months of life. until 1 year from last patient enrolled
Secondary Rate of patients receiving systemic treatment in the last month of life Identification of the rate of patients receiving systemic treatment in the last month of life until 1 year from last patient enrolled
Secondary Rate of patients with a tracheostomy performed in the last 3 months of life Identification of the rate of patients with tracheostomy performed in the last 3 months of life. until 1 year from last patient enrolled
Secondary Rate of patients with gastrostomy performed in the last 3 months of life Identification of the rate of patients with gastrostomy performed in the last 3 months of life. until 1 year from last patient enrolled
Secondary Caregiver/family members' satisfaction (FAMcare questionnaire) at 15 weeks Assessment of the caregiver/family members' satisfaction. Minimum = -99; Maximum = +99; higher means better outcome. at 15 weeks
Secondary Overall Survival (OS) Overall Survival until 1 year from last patient enrolled
Secondary Prediction error of survival (defined as the difference between actual survival (AS) of patients and clinician prediction of survival (CPS)) Accuracy of physician prediction of survival until 1 year from last patient enrolled
See also
  Status Clinical Trial Phase
Recruiting NCT05980598 - TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02548377 - Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Terminated NCT02975739 - Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors N/A
Recruiting NCT00982436 - Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer Phase 1/Phase 2
Completed NCT01025518 - DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients N/A
Active, not recruiting NCT00248235 - Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer Phase 2/Phase 3
Completed NCT00135161 - Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer Phase 1
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Not yet recruiting NCT06458517 - Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers N/A
Completed NCT05269342 - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer N/A
Recruiting NCT05544136 - A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer Phase 2
Terminated NCT03286972 - PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Recruiting NCT04435938 - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT03678649 - A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC Phase 2
Recruiting NCT03975465 - EMST and Swallowing in Long-Term Survivors of HNCA N/A
Completed NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2
Completed NCT06446570 - Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma Phase 2
Completed NCT02284802 - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy N/A